Mesirow Financial Investment Management Inc. Sells 2,591 Shares of Johnson & Johnson $JNJ

Mesirow Financial Investment Management Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 2.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,282 shares of the company’s stock after selling 2,591 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Johnson & Johnson were worth $21,931,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Abich Financial Wealth Management LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the second quarter worth about $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. boosted its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc increased its holdings in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $245.32 on Thursday. The firm has a market cap of $591.19 billion, a PE ratio of 22.20, a PEG ratio of 2.39 and a beta of 0.35. The stock has a 50 day moving average of $223.12 and a 200 day moving average of $200.79. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $247.25.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Bank of America raised their price objective on shares of Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a report on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating and set a $250.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Argus boosted their target price on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Leerink Partners boosted their target price on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. Finally, Barclays lifted their price target on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $232.70.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong product momentum: J&J’s oncology franchise (Darzalex) and new data for Tremfya are driving revenue upside and underpinning investor confidence in sustainable growth. Can J&J Sustain Its Double-Digit Oncology Growth Streak?
• Positive Sentiment: FDA filing for a rare-disease drug: J&J submitted an sBLA for IMAAVY (nipocalimab) as a first-ever treatment for wAIHA — approval would add a high-value orphan indication and expand the pipeline. PR Newswire: J&J seeks FDA approval of IMAAVY
• Positive Sentiment: Strategic pivot and MedTech tailwinds: Coverage highlights J&J’s shift into higher-margin medical devices, robotics and Shockwave/IVL tech, supporting margin expansion and a path to ~$100B revenue guidance. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Positive Sentiment: Potential DePuy Synthes divestiture: Reports that J&J is exploring a major sale of its orthopedics unit could unlock significant cash and simplify the business, a clear value-creation catalyst if executed. J&J Eyes Mega Sale Of DePuy Synthes
• Neutral Sentiment: Analyst moves and valuation tweaks: Street price targets have been nudged modestly higher, but changes are incremental — supportive but not a strong directional signal. How Shifting Analyst Targets Are Rewriting The J&J Investment Story
• Neutral Sentiment: Corporate tech & partnerships story: Reports on J&J’s enterprise tech investments and a first co-funding with Blackstone highlight long-term transformation, but near-term financial impact is unclear. Enterprise Technology Analysis Report
• Negative Sentiment: Bayer lawsuit and legal overhang: Bayer sued over survival-claim marketing for a prostate cancer drug, adding litigation risk and headline volatility for Janssen’s oncology unit. Bayer files lawsuit against J&J
• Negative Sentiment: Insider selling: EVP Timothy Schmid disclosed sales totaling thousands of shares in recent filings — routine but sometimes perceived negatively as profit-taking. SEC Form 4: Timothy Schmid

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.